Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Generic Drug Firms Willing To Do Pediatric Studies If Deferred, NAPM Says

Executive Summary

Generic drug companies are willing to conduct pediatric studies for ANDAed products, if such studies were deferred until after approval, the National Association of Pharmaceutical Manufacturers told the agency in an Oct. 26 citizens petition.

You may also be interested in...

GPIA Takes Firm Stance Against Required Pediatric Studies For Generics

Generic drug sponsors bear no responsibility for pediatric studies for multisource drugs, the Generic Pharmaceutical Industry Association told FDA in March 3 comments on implementation of FDAMA pediatric exclusivity provisions and the agency's pediatric rule.

Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011



Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts